Phase 4 N=43 The Effect of Lumify™ Eyedrops on Eyelid Position
Eyelid Droop
Primary: Palpebral Fissure Height — 9.64; 9.66; 9.92; 9.96 milimeter
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=16 Clinical Trial Comparing Two Non-Surgical Treatments for Severe Blepharoptosis
Blepharoptosis · Ptosis, Eyelid · Myasthenia Gravis
Primary: Interpalpebral Fissure (IPF) During Spontaneous Blink — 2.4; 4.1; 1.1 millimeters — p=<0.001
Phase 4 N=18 Phenylephrine Versus Eyelid Taping for Muller's Muscle-Conjunctival Resection (MMCR) Evaluation
Ptosis, Eyelid
Primary: Mean MRD1 After Phenylephrine — 2.08 mm
Early Phase 1 N=15 Topical Bimatoprost for Chemical Blepharoplasty
Dermatochalasis
Primary: Graded Change in Dermatochalasis — .2679 units on a scale
Phase 2 N=46 Safety and Efficacy Study of RVL-1201 in Acquired Blepharoptosis
Blepharoptosis
Primary: Humphrey Visual Field — 9.8; 12.1; 11.1; 16.1 Points seen
Phase 2 N=33 LEV102 Topical Gel in Acquired Blepharoptosis
Acquired Blepharoptosis
Primary: Percentage of Subjects With Treatment-Emergent Adverse Events [Safety and Tolerability]) — 0; 0; 0 Participants
Phase 3 N=140 Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis
Acquired Blepharoptosis
Primary: Mean Change in Number of Points Seen on the Leicester Peripheral Field Test (LPFT) in RVL-1201 Group vs. Vehicle Group — 5.2; 1.5; 6.4; 2.2 Points seen — p=<0.0001
N/A N=19 Clinical Trial to Improve the Magnetic Levator Prosthesis
Blepharoptosis · Ptosis, Eyelid · Myasthenia Gravis
Primary: Change in Interpalpebral Fissure During Eye Opening — 4.5; 6.9; 6.2; 6.3 millimeters — p=>=0.46
Phase 3 N=164 Study of Safety and Efficacy of RVL-1201 in the Treatment of Blepharoptosis
Blepharoptosis
Primary: Mean Change in Number of Points Seen on the Leicester Peripheral Field Test (LPFT) in RVL-1201 Group vs. Vehicle Group — 6.3; 2.1; 7.7; 2.4 Points seen — p=<0.0001
Phase 3 N=234 Study of Safety of RVL-1201 in Treatment of Blepharoptosis
Blepharoptosis
Primary: Mean Change From Baseline in Intraocular Pressure (IOP) at Day 84 — -0.6; -0.2; -0.6; -0.2 mmHg
N/A N=11 Magnetic Correction of Eye Lid Paralysis
Blepharoptosis · Lagophthalmos · Facial Paralysis
Primary: Rating Scale of Skin Integrity — 0.3 units on a scale
Phase 2 N=90 Phase 2 Study of XAF5 (XOPH5) Ointment for Reduction of Excess Eyelid Fat (Steatoblepharon)
Lower Eyelid Steatoblepharon (Excess Eyelid Fat)
Primary: Lower Eyelid Steatoblepharon Severity (LESS) Score--Clinician-Reported — 27; 6 participants — p=0.020
N/A N=19 Intense Pulse Light Treatment With Meibomian Gland Expression of the Upper Eyelids in Dry Eye Disease
Dry Eye
Primary: Non-invasive Tear Break up Time (TBUT) — 3.9; 4.0 seconds
Phase 4 N=114 The Effect of Upneeq (Oxymetazoline Hydrochloride 0.1%) on Eyelid Position, Eye Redness, and Eye Appearance
Ptosis, Eyelid · Conjunctiva Inflamed · Eye Manifestations
Primary: Change in Palpebral Fissure Height — 1.1; -0.4 mm
N/A N=80 A Prospective, Open Label Study Evaluating JUVÉDERM® VOLBELLA With Lidocaine Treatment for the Correction of Skin Depressions in the Infra-orbital Area
Infra-orbital Skin Depressions
Primary: Percentage of Subjects With a ≥1 Grade Improvement From Baseline in Infra-Orbital Area on the Allergan Infra-Orbital Rating Scale (AIRS) on the Right and Left Side — 99…
Phase 4 N=19 Tear Lipid Layer Thickness With Emollient Eye Drops
Dry Eye Syndromes
Primary: Change in Tear Lipid Layer Thickness — 4.8; 8.8 nm
Phase 4 N=18 Rejuvenation of the Lower Eyelid Using a Combination of Two Hyaluronic Acid Fillers - a Pilot Study
Infraorbital Hollows
Primary: The Primary Objective of This Study is to Determine the Efficacy and Longevity of the Use of Restylane® and Perlane® in Combination for the Rejuvenation of the…
N/A N=30 Impact of Soft Contact Lenses on Lid-Parallel Conjunctival Folds
Lid-Parallel Conjunctival Folds
Primary: Lid-Parallel Conjunctival Folds (LIPCOF) — 1.95; 1.75; 1.70; 1.40 Score
N/A N=40 Photographic Assessment of Eyebrow Position and Range of Motion
Brow Ptosis
Primary: Eyebrow Position — -3.22 mm
N/A N=7 Minimally Invasive Holmium:YAG Laser Blepharoplasty
Lower Eyelid Entropion
Primary: Change in Lower Eyelid Bags. — 5; 5 Participants
Phase 3 N=25 Assess Aesthetic Improvement With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glabellar Lines
Glabellar Frown Lines · Canthal Lines
Primary: Responders Rate Using the Global Aesthetic Improvement Scale (GAIS) at Maximum Frown (Glabellar Lines) — 100 percentage of participants
N/A N=264 Silicone Gel for Postsurgical Scars of the Eyelid
Scarring Due to Treatment
Primary: Post-operative Scarring - Erythema — 1.67; 1.70; 1.50; 1.65 score on a scale — p=0.48
Phase 4 N=65 Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm
Blepharospasm
Primary: Change From Baseline to Week 4 in Blepharospasm Disability Index — -2.8; -1.3 Points on Scale
Phase 3 N=303 Treatment of Moderate to Severe Lateral Canthal Lines
Lateral Canthal Lines
Primary: Percentage of Subjects With a ≥ 2-grade Improvement From Baseline on the Lateral Canthal Line Investigator and Subject Assessments at Maximum Smile at One Month. — 106…
Phase 3 N=235 MT10109L in the Treatment of Lateral Canthal Lines
Lateral Canthal Lines
Primary: The Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the Facial Wrinkle Scale With Photonumeric Guide (FWS) According to INVESTIGATOR AND…
Phase 2 N=24 Eyelid Androgen Treatment in Dry Eye
Aqueous Tear Deficiency · Meibomian Gland Dysfunction of Bilateral Eyes (Disorder)
Primary: Tear Break up Time — 0.0; 2.9 seconds
Phase 2 N=48 ET-01 in Subjects With Lateral Canthal Lines
Lateral Canthal Lines · Crow's Feet
Primary: Number of Participants With a Response Defined as IGA-C (Investigators Global Assessment) Score ≤ 2 and a SSA-C (Subject Self-Assessment) Score ≤ 2 — 2; 3; 4; 2…
N/A N=179 Epidemiologic Analysis of Change in Eyelash Characteristics With Age in Healthy Women
Health
Primary: Eyelash Length as Measured by Digital Image Analysis (DIA) — 7.33 Millimeters (mm)
Phase 3 N=61 Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Abnormal Contraction or Twitch of the Eyelid
Bilateral Blepharospasm (BEB)
Primary: Double-blind MP: Change From Baseline in JRS Severity Subscore at Day 43 (Visit 4) — -0.6; -1.0; -1.8 score on a scale — p==0.0004
Phase 2 N=38 ET-01 in Subjects With Lateral Canthal Lines, LCL-209
Lateral Canthal Lines, LCL · Crow's Feet
Primary: Number of Participants With a Response Defined as Change in IGA-C (Investigators Global Assessment) Score by at Least 2 Ordinals From Baseline to Week 4 — 3; 1…